Tinos Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-09-26.
Tinos Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on September 26, 2025. The filing reports $2.25M sold. Its industry group is Biotechnology. It names Nikolaos Tapinos (Executive Officer, Director), David Karambizi (Executive Officer, Director), Anastasios Polimenakos (Director) (SEC Form D/A, September 26, 2025).
Is this your company?
Sell to companies like Tinos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-26 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Tinos Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Tinos Therapeutics, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Tinos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Tinos Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Tinos Therapeutics, Inc. →Get the full cited report on Tinos Therapeutics, Inc.
What the filing shows about Tinos Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tinos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Tinos Therapeutics, Inc.'s address as 34 Boyce Avenue, Barrington, RI 02806.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Tinos Therapeutics, Inc. →
Amended on 2026-04-17: the offering size changed from $1,500,000 to $4,000,000; the amount sold changed from $1,000,000 to $2,250,000; the number of investors changed from 1 to 3. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Tinos Therapeutics, Inc. See pricing
Tinos Therapeutics, Inc. is a registered filer with the SEC (CIK 2088485) and has filed since 2025-09-26. 2 filings are on record, the latest on 2026-04-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Tinos Therapeutics, Inc.'s Form D of 2025-09-26 names Nikolaos Tapinos, David Karambizi and Anastasios Polimenakos as its officers, directors or promoters.
Its new offerings report $1M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Nikolaos Tapinos is named as Executive Officer and Director on the Form D that Tinos Therapeutics, Inc. filed with the SEC on 26 September 2025, one of 3 people that filing names.
David Karambizi is named as Executive Officer and Director on the Form D that Tinos Therapeutics, Inc. filed with the SEC on 26 September 2025, one of 3 people that filing names.
Anastasios Polimenakos is named as Director on the Form D that Tinos Therapeutics, Inc. filed with the SEC on 26 September 2025, one of 3 people that filing names.
3 people named on the filing — 2 holding an executive role and 1 as a director only.
Named as of the 2025-09-26 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Tinos Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tinos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tinos Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Tinos Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Tinos Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Tinos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/tinos-therapeutics-inc-form-d-25000001